출판 : MarketsandMarkets（마켓츠앤드마켓츠）출판년월 : 2022년01월
・기술(재조합, 톡소이드, 결합형, RNA), 유형(단가, 다가), 질환(폐렴구균, 인플루엔자, DTP, HPV, MMR, COVID-19), 투여 경로(IM, SC, 경구 ), 최종 사용자(소아과, 성인) – 2026년까지의 세계 예측
Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) – Global Forecast to 2026
| 페이지수 | 293 |
| 도표수 | 300 |
| 구성 | 영문조사보고서 |
| 가격 |
세계의 신형 코로나 백신을 포함한 백신 시장은 2021년에 1,394억 달러, 2026년에는 1,492억 달러에 이를 것으로 예측된다. 신형 코로나 백신을 제외한 세계 시장은 2021년에 414억 달러, 2026년까지는 672억 달러에 달하며 2021년부터 2026년까지 CAGR 10.2%로 성장할 것으로 예측됨。
MarketsandMarkets「백신 시장: 기술(재조합, 톡소이드, 결합형, RNA), 유형(단가, 다가), 질환(폐렴구균, 인플루엔자, DTP, HPV, MMR, COVID-19), 투여 경로(IM, SC, 경구 ), 최종 사용자(소아과, 성인) – 2026년까지의 세계 예측 – Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) – Global Forecast to 2026」는 세계의 백신 시장을 조사하여 질환, 투여 경로, 최종 사용자 등의 중요한 세그먼트별 분석 및 예측 결과를 제공하고 있습니다。
MarketsandMarkets 조사결과
- 바인딩 백신은 기술 세그먼트에서 가장 큰 점유율을 차지했다. (신형 코로나 백신 제외)
- 2020년 대상 질환별 점유율은 폐렴구균 감염증이 가장 컸다.
- 백신의 종류에서는 단맛 백신의 점유율이 가장 크다.
- 최종 사용자별로는 소아용 백신의 점유율이 가장 크다.
- 투여 유형별로는 근육 주사와 피하 주사의 점유율이 가장 크다.
- 2020년 지역별 점유율은 북미가 가장 컸다.
주요 게재 내용
-
- 시장 개요
- 기술별 백신 시장
- 결합형 백신
- 재조합 백신
- 비활성화 백신 및 서브유닛 백신
- 약독생 백신
- 톡소이드 백신
- 바이러스 벡터 백신
- 타입별 백신 시장
- 단맛 백신(단가 백신)
- 혼합 백신(다가 백신)
- 대상 질환별 백신
- 폐렴 구균 감염
- 독감
- 인체 유두종 바이러스 감염(HPV)
- 수막염균성 질환
- 포진포진
- 로타바이러스
- MMR(홍역, 오타후쿠카제, 풍진)
- 수두
- 간염
- DTP (디프테리아, 백일해, 파상풍)
- 폴리오
- 신형 코로나 바이러스 감염
- 기타 대상 질환
- 투여방법별 백신시장
- 근육 주사 및 피하 주사
- 경구 투여
- 기타 투여 방법
- 최종 사용자별 백신 시장
- 아동용 백신
- 성인 백신
- 지역별 백신 시장
- 북미
- 유럽
- 아시아 태평양 지역
- 라틴 아메리카
- 중동 및 아프리카
- 경쟁 환경
- 기업 정보
- 부록
The global vaccines market (including COVID-19 vaccines) is projected to reach USD 149.2billion by 2026 from USD 139.4 billion in 2021 during the forecast period. The global vaccines market (excluding COVID-19 vaccines) is projected to reach USD 67.2billion by 2026 from USD 41.4 billion in 2021, at a CAGR of 10.2% from 2021 to 2026. Market growth is largely driven by the rise of emerging and re-emerging infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government support for vaccine development, and the rising focus on immunization. However, the huge capital investments required for developing vaccines and low purchasing power in developing countries may restrain the market growth.
“Conjugate vaccines segment accounted for the largest share of the technology segment (excluding COVID 19 vaccines)”
Based on technology, the vaccines market (excluding COVID 19 vaccines) has been segmented into conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and viral vector vaccines. The conjugate vaccines segment accounted for the largest share of the global vaccines market (excluding COVID-19 vaccines), by technology, in 2020. The large share of this segment can be attributed to the increasing government support and rising company investments in conjugate vaccine development.
“The Pneumococcal disease segment accounted for the largest share in 2020”
Based on disease indication, the vaccines market is segmented into pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. The pneumococcal disease segment accounted for the largest share of the vaccines market, by disease indication, in 2020. The large share of this segment is attributed to the high incidence of pneumococcal disease and increasing government investments in pneumococcal vaccination programs.
“Monovalent vaccines segment accounted for the largest share of the type segment”
Based on type, the global vaccines market is segmented into monovalent and multivalent vaccines. The monovalent vaccines segment accounted for the largest share of the global vaccines market (excluding COVID-19 vaccines) in 2020. Growing disease prevalence has prompted initiatives for immunization against specific infectious diseases such as COVID 19. This has led to large market share for monovalent vaccines. Rising prevalence of emerging and re-emerging infectious diseases and R&D initiatives will contrive to drive the market for monovalent vaccines.
“Pediatric vaccines segment accounted for the largest share of the end user segment”
Based on end user, the global vaccines market is segmented into pediatric and adult users. In 2020, the pediatric users segment accounted for the largest share the vaccines market (excluding COVID 19 vaccines), while the adult user segment is estimated to register the highest CAGR during the forecast period. Increased initiatives from government and non-government organizations and increasing company initiatives to develop advanced pediatric vaccines for preventing diseases are expected to drive market growth for pediatric vaccines.
“Intramuscular & Subcutaneous route of administration segment accounted for the largest share of the route of administration segment”
Based on the route of administration, the vaccines market is segmented into intramuscular and subcutaneous administration, oral administration, and other routes of administration. In 2020, the intramuscular and subcutaneous administration segment accounted for the largest share of the vaccines market (excluding COVID-19 vaccines). Intramuscular & Subcutaneous is one of the most prevalent route of administration for vaccines due to its precise control of dose and administration rate, rapid exposure to antigen, and ease of administration.
“North America was the largest regional market for Vaccines market in 2020”
Based on the region, the vaccines market is broadly segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the vaccines market in 2020. The high prevalence of infectious diseases, increasing investments by government organizations for vaccine development, increasing R&D investments by market players, and mandatory reporting are some of the key factors driving the vaccines market in North America.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80%and Demand Side 20%
- By Designation: Managers – 55%, CXOs – 20%, and Executives – 25%
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
Lists of Companies Profiled in the Report:
• GlaxoSmithKline Plc (UK)
• Merck & Co., Inc. (US)
• Pfizer, Inc. (US)
• Sanofi SA (France)
• CSL Limited (Australia)
• Emergent BioSolutions, Inc. (US)
• Johnson & Johnson (US)
• AstraZeneca Plc (UK)
• Serum Institute of India Pvt. Ltd. (India)
• Bavarian Nordic A/S (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Panacea Biotec, Ltd. (India)
• Biological E. Limited (India)
• Bharat Biotech Ltd. (India)
• Novavax, Inc. (US)
• FSUE NPO Microgen (Russia)
• Sinovac Biotech, Ltd. (China)
• Incepta Vaccine Limited (Bangladesh)
• Valneva SE (France), VBI Vaccines (US)
• PT Bio Frama (Persero) (Indonesia)
• Inovio Pharmaceuticals, Inc. (US)
• Chongqing Zhifei Biological Products Co. Ltd. (China)
• Indian Immunologicals Limited (India)
Research Coverage:
This report provides a detailed picture of the vaccines market. It aims at estimating the size and future growth potential of the market across different segments such as thetechnology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis ofthe key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers,restraints,trends,challenges and opportunities.
목차
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 39
1.2.1 INCLUSIONS & EXCLUSIONS 39
TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS 39
1.3 MARKET SCOPE 40
1.3.1 MARKETS COVERED 40
FIGURE 1 VACCINES MARKET SEGMENTATION 40
1.3.2 YEARS CONSIDERED FOR THE STUDY 41
1.4 CURRENCY 41
1.5 LIMITATIONS 41
1.6 STAKEHOLDERS 42
1.7 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 44
2.1 RESEARCH DATA 44
FIGURE 2 RESEARCH DESIGN 44
2.1.1 SECONDARY DATA 45
2.1.2 PRIMARY DATA 46
FIGURE 3 BREAKDOWN OF PRIMARIES: VACCINES MARKET 46
2.2 MARKET ESTIMATION METHODOLOGY 47
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020 47
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 49
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 49
2.3 MARKET GROWTH RATE PROJECTIONS 50
FIGURE 6 CAGR PROJECTIONS (SUPPLY-SIDE): VACCINES MARKET (EXCLUDING
COVID-19 VACCINES) 50
FIGURE 7 VACCINES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS 51
2.4 DATA TRIANGULATION 52
FIGURE 8 DATA TRIANGULATION METHODOLOGY 52
2.5 RESEARCH ASSUMPTIONS 53
2.6 RISK ANALYSIS 53
3 EXECUTIVE SUMMARY 54
FIGURE 9 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 54
FIGURE 10 COVID-19 VACCINES MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 55
FIGURE 11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2021 VS. 2026 (USD MILLION) 55
FIGURE 12 VACCINES MARKET, BY DISEASE INDICATION, 2021 VS. 2026 (USD MILLION) 56
FIGURE 13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD MILLION) 57
FIGURE 14 VACCINES MARKET SHARE (EXCLUDING COVID-19 VACCINES), BY END USER, 2021 VS. 2026 57
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET (EXCLUDING
COVID-19 VACCINES) 58
4 PREMIUM INSIGHTS 60
4.1 VACCINES MARKET OVERVIEW (EXCLUDING COVID-19 VACCINES) 60
FIGURE 16 GROWING PREVALENCE OF EMERGING AND RE-EMERGING INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 60
4.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY AND COUNTRY (2020) 61
FIGURE 17 CONJUGATE VACCINES ACCOUNTED FOR THE LARGEST SHARE OF
THE NORTH AMERICAN VACCINES MARKET IN 2020 61
4.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES 62
FIGURE 18 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE VACCINES MARKET FROM 2021 TO 2026 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
FIGURE 19 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
5.2.1 DRIVERS 64
5.2.1.1 Growing prevalence of emerging and re-emerging infectious diseases 64
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 65
5.2.1.2 Increasing focus on immunization programs 65
5.2.1.3 Growing government support for vaccine development 66
TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION) 67
5.2.1.4 Increasing industry initiatives to enhance vaccine R&D 67
5.2.2 RESTRAINTS 67
5.2.2.1 High cost of vaccine development 67
5.2.2.2 Low purchasing power in developing countries 68
5.2.3 OPPORTUNITIES 68
5.2.3.1 High growth prospects in emerging markets 68
5.2.3.2 Focus on therapeutic vaccines 68
5.2.3.3 Use of adjuvants in vaccines 69
5.2.4 CHALLENGES 69
5.2.4.1 Inequitable access to vaccines 69
TABLE 4 IMMUNIZATION COVERAGE, BY DISEASE, 2020 70
5.2.4.2 Vaccine misinformation 70
5.3 IMPACT OF COVID-19 ON THE VACCINES MARKET 70
TABLE 5 APPROVED COVID-19 VACCINES (NOVEMBER 2021) 71
TABLE 6 COVID-19 VACCINES PIPELINE 72
FIGURE 20 VACCINES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021 (USD BILLION) 73
5.4 RANGES/SCENARIO 74
FIGURE 21 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE VACCINES MARKET 74
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 75
FIGURE 22 REVENUE SHIFT & NEW REVENUE POCKETS FOR VACCINE PROVIDERS 75
5.6 PATENT ANALYSIS 76
FIGURE 23 PATENTS GRANTED FOR VACCINES IN THE LAST 10 YEARS 76
TABLE 7 INDICATIVE LIST OF PATENTS IN THE VACCINES MARKET 76
5.7 PRICING ANALYSIS 77
TABLE 8 MEDIAN PRICE PER DOSE OF SOME VACCINES (2020) (USD) 77
5.8 VALUE CHAIN ANALYSIS 78
FIGURE 24 VALUE CHAIN ANALYSIS OF THE VACCINES MARKET: R&D AND CLINICAL TRIAL PHASE CONTRIBUTES MAXIMUM VALUE 78
5.9 ECOSYSTEM ANALYSIS 79
FIGURE 25 ECOSYSTEM ANALYSIS: VACCINES MARKET 79
5.10 REGULATORY LANDSCAPE 79
FIGURE 26 REGULATORY APPROVAL PROCESS FOR VACCINES 79
5.10.1 NORTH AMERICA 80
5.10.2 EUROPE 80
TABLE 9 REGULATORY AUTHORITIES IN EUROPE 80
5.10.3 ASIA PACIFIC 81
TABLE 10 REGULATORY AUTHORITIES IN ASIA PACIFIC 81
5.10.4 REST OF THE WORLD 81
5.11 PORTER’S FIVE FORCES ANALYSIS 82
TABLE 11 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 82
5.11.1 THREAT OF NEW ENTRANTS 82
5.11.2 THREAT OF SUBSTITUTES 82
5.11.3 BARGAINING POWER OF BUYERS 83
5.11.4 BARGAINING POWER OF SUPPLIERS 83
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 83
5.12 KEY PIPELINE PRODUCTS 83
TABLE 12 KEY PIPELINE VACCINES: GLAXOSMITHKLINE PLC (UK) 83
TABLE 13 KEY PIPELINE VACCINES: PFIZER, INC. (US) 84
TABLE 14 KEY PIPELINE VACCINES: MERCK & CO., INC. (US) 85
TABLE 15 KEY PIPELINE VACCINES: SANOFI S.A. (FRANCE) 85
5.13 NEW VACCINE OPPORTUNITIES 86
5.13.1 HIV 86
5.13.1.1 HIV vaccines pipeline 86
5.13.1.2 HIV vaccines: Public-private initiatives and funding 88
5.13.2 MALARIA 89
5.13.2.1 Malaria vaccines pipeline 89
5.13.2.2 Malaria vaccines: Public-private initiatives and funding 90
5.13.3 ZIKA 90
5.13.3.1 Zika vaccines pipeline 90
5.13.3.2 Zika vaccines: Public-private initiatives and funding 91
5.13.4 EBOLA 91
5.13.4.1 Ebola vaccines pipeline 91
5.13.4.2 Ebola vaccines: Public-private initiatives and funding 92
5.13.4.3 Ebola projects funded by EC (2014–2020) 92
6 VACCINES MARKET, BY TECHNOLOGY 93
6.1 INTRODUCTION 94
TABLE 16 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION) 94
TABLE 17 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 95
6.2 CONJUGATE VACCINES 95
6.2.1 CONJUGATE VACCINES HOLD THE LARGEST SHARE OF THE MARKET 95
TABLE 18 COST OF PEDIATRIC MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN THE US 96
TABLE 19 COST OF ADULT MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN
THE US 97
TABLE 20 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION) 97
TABLE 21 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 22 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 98
TABLE 23 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 98
TABLE 24 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 98
6.3 RECOMBINANT VACCINES 99
6.3.1 LACK OF POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES ARE DRIVING R&D ON RECOMBINANT VACCINES 99
TABLE 25 EXAMPLES OF RECOMBINANT VACCINES 99
TABLE 26 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION) 100
TABLE 27 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 100
TABLE 28 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 100
TABLE 29 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 101
TABLE 30 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 101
6.4 INACTIVATED & SUBUNIT VACCINES 101
6.4.1 EASE OF STORAGE AND TRANSPORTATION HAVE MADE INACTIVATED & SUBUNIT VACCINES POPULAR 101
TABLE 31 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 102
TABLE 32 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION) 103
TABLE 33 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 103
TABLE 34 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 103
TABLE 35 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 104
TABLE 36 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 104
6.5 LIVE ATTENUATED VACCINES 104
6.5.1 ISSUES IN PRESERVING AND MAINTAINING LIVE ATTENUATED VACCINES HAVE SLOWED MARKET GROWTH 104
TABLE 37 EXAMPLES OF LIVE ATTENUATED VACCINES 105
TABLE 38 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION) 105
TABLE 39 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 40 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 41 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 42 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 107
6.6 TOXOID VACCINES 107
6.6.1 COMPANY INITIATIVES AND THE INTRODUCTION OF NEW VACCINES WILL SUPPORT MARKET GROWTH 107
TABLE 43 EXAMPLES OF TOXOID VACCINES 108
TABLE 44 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION) 108
TABLE 45 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 109
TABLE 46 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION) 109
TABLE 47 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 109
TABLE 48 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 110
6.7 VIRAL VECTOR VACCINES 110
6.7.1 VIRAL VECTOR VACCINES USE THE BODY’S OWN CELLS TO PRODUCE ANTIGENS 110
TABLE 49 EXAMPLES OF RECENTLY LAUNCHED VIRAL VECTOR VACCINES 110
TABLE 50 VIRAL VECTOR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION) 111
7 VACCINES MARKET, BY TYPE 112
7.1 INTRODUCTION 113
TABLE 51 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION) 113
TABLE 52 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION) 113
7.2 MONOVALENT VACCINES 114
7.2.1 MONOVALENT VACCINES DOMINATE THE VACCINES MARKET 114
TABLE 53 EXAMPLES OF MONOVALENT VACCINES 114
TABLE 54 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION) 115
TABLE 55 NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION) 115
TABLE 56 EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 115
TABLE 57 ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 58 LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION) 116
7.3 MULTIVALENT VACCINES 116
7.3.1 INCREASING INITIATIVES BY COMPANIES TO DEVELOP NEW MULTIVALENT VACCINES TO DRIVE MARKET GROWTH 116
TABLE 59 EXAMPLES OF MULTIVALENT VACCINES 117
TABLE 60 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION) 118
TABLE 61 NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION) 118
TABLE 62 EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 118
TABLE 63 ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 119
TABLE 64 LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION) 119
8 VACCINES MARKET, BY DISEASE INDICATION 120
8.1 INTRODUCTION 121
TABLE 65 VACCINES MARKET, BY DISEASE INDICATION, 2019–2026 (USD MILLION) 121
8.2 PNEUMOCOCCAL DISEASE 122
8.2.1 PNEUMOCOCCAL DISEASE IS THE LARGEST DISEASE INDICATION SEGMENT OF THE MARKET 122
TABLE 66 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN
THE MARKET 122
TABLE 67 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2019–2026 (USD MILLION) 123
TABLE 68 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 123
TABLE 69 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY BUYER,
2019–2026 (MILLION DOSES) 123
8.3 INFLUENZA 124
8.3.1 RISING DEMAND FOR INFLUENZA VACCINES FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET GROWTH 124
TABLE 70 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET 125
TABLE 71 INFLUENZA VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 125
TABLE 72 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 126
8.4 COMBINATION VACCINES 126
8.4.1 INCREASING DEMAND FOR ALL-IN-ONE VACCINES IS DRIVING THE GROWTH OF THIS SEGMENT 126
TABLE 73 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES IN
THE MARKET 127
TABLE 74 COMBINATION VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 128
TABLE 75 NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
8.5 HPV 128
8.5.1 HPV VACCINES MARKET TO GROW AT THE HIGHEST RATE DURING
THE FORECAST PERIOD 128
TABLE 76 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 129
TABLE 77 HPV VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 130
TABLE 78 NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 130
TABLE 79 HPV VACCINES MARKET, BY BUYER, 2019–2026 (MILLION DOSES) 130
8.6 MENINGOCOCCAL DISEASE 131
8.6.1 RISING INCIDENCE OF MENINGOCOCCAL DISEASE TO SUPPORT
THE GROWTH OF THIS SEGMENT 131
TABLE 80 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES IN THE MARKET 131
TABLE 81 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2019–2026 (USD MILLION) 132
TABLE 82 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 132
8.7 HERPES ZOSTER 132
8.7.1 HERPES ZOSTER VACCINES TO WITNESS STABLE DEMAND DURING
THE FORECAST PERIOD 132
TABLE 83 HERPES ZOSTER VACCINES MARKET, BY REGION,
2019–2026 (USD MILLION) 133
TABLE 84 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 133
8.8 ROTAVIRUS 133
8.8.1 RISING INCIDENCE OF ROTAVIRUS INFECTIONS TO DRIVE MARKET GROWTH 133
TABLE 85 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET 134
TABLE 86 ROTAVIRUS VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 134
TABLE 87 NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 134
TABLE 88 ROTAVIRUS VACCINES MARKET, BY BUYER, 2019–2026 (MILLION DOSES) 135
8.9 MMR 135
8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA IS SUPPORTING THE GROWTH OF THIS SEGMENT 135
TABLE 89 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET 135
TABLE 90 MMR VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 136
TABLE 91 NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 136
8.10 VARICELLA 136
8.10.1 PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE THE DEMAND FOR VARICELLA VACCINES 136
TABLE 92 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET 137
TABLE 93 VARICELLA VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 137
TABLE 94 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 137
8.11 HEPATITIS 138
8.11.1 HIGH PREVALENCE OF HEPATITIS INFECTIONS TO DRIVE THE DEMAND FOR IMMUNIZATION 138
TABLE 95 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET 138
TABLE 96 HEPATITIS VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 139
TABLE 97 NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 139
8.12 DTP 139
8.12.1 INCREASING ACCESSIBILITY OF DTP VACCINES IN DEVELOPING COUNTRIES TO DRIVE MARKET GROWTH 139
TABLE 98 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET 140
TABLE 99 DTP VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 140
TABLE 100 NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 140
8.13 POLIO 141
8.13.1 GOVERNMENT INITIATIVES TO SUPPORT THE GROWTH OF THIS SEGMENT 141
TABLE 101 POLIO VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 142
TABLE 102 NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 142
8.14 COVID-19 142
8.14.1 EMERGENCE OF SARS-COV-2 VARIANTS COULD MAKE BOOSTER DOSES NECESSARY 142
TABLE 103 LIST OF WHO PREQUALIFIED COVID-19 VACCINES 143
TABLE 104 COVID-19 VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 143
TABLE 105 NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 144
TABLE 106 COVID-19 VACCINE DELIVERIES, BY COUNTRY (MILLION DOSES) 144
8.15 OTHER DISEASE INDICATIONS 145
TABLE 107 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 145
TABLE 108 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2019–2026 (USD MILLION) 146
TABLE 109 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 146
9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 147
9.1 INTRODUCTION 148
TABLE 110 VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 148
TABLE 111 VACCINES MARKET (INCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 148
9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 149
9.2.1 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION ACCOUNTED FOR THE LARGEST MARKET SHARE 149
TABLE 112 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 149
TABLE 113 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION,
2019–2026 (USD MILLION) 150
TABLE 114 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION) 150
TABLE 115 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION) 151
TABLE 116 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION) 151
TABLE 117 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION) 152
9.3 ORAL ADMINISTRATION 152
9.3.1 POSSIBILITY OF IRRITATION OF THE GASTRIC MUCOSA IS LIMITING
THE GROWTH OF THIS SEGMENT 152
TABLE 118 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION) 153
TABLE 119 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 153
TABLE 120 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 153
TABLE 121 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 154
TABLE 122 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION) 154
9.4 OTHER ROUTES OF ADMINISTRATION 154
TABLE 123 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION) 155
TABLE 124 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION) 155
TABLE 125 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION) 156
TABLE 126 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 156
TABLE 127 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION) 156
10 VACCINES MARKET, BY END USER 157
10.1 INTRODUCTION 158
TABLE 128 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2019–2026 (USD MILLION) 158
10.2 PEDIATRIC VACCINES 158
10.2.1 PEDIATRIC VACCINES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET 158
TABLE 129 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION) 159
TABLE 130 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 159
TABLE 131 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 160
TABLE 132 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 160
TABLE 133 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 160
10.3 ADULT VACCINES 161
10.3.1 ADULT VACCINES SEGMENT TO GROW AT THE HIGHEST CAGR DURING
THE FORECAST PERIOD 161
TABLE 134 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION) 162
TABLE 135 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 162
TABLE 136 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION) 162
TABLE 137 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 163
TABLE 138 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION) 163
11 VACCINES MARKET, BY REGION 164
11.1 INTRODUCTION 165
FIGURE 27 VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES (EXCLUDING COVID-19 VACCINES) 165
TABLE 139 VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION) 166
TABLE 140 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2019–2026 (USD MILLION) 166
11.2 NORTH AMERICA 167
FIGURE 28 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 168
TABLE 141 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION) 169
TABLE 142 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION) 169
TABLE 143 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 170
TABLE 144 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION) 170
TABLE 145 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 170
TABLE 146 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 171
11.2.1 US 171
11.2.1.1 The US is the largest market for vaccines globally 171
TABLE 147 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION) 172
TABLE 148 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION) 172
TABLE 149 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION) 173
TABLE 150 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 173
TABLE 151 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION) 173
11.2.2 CANADA 174
11.2.2.1 High incidence of infectious diseases is driving the demand for vaccines in the country 174
TABLE 152 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION) 174
TABLE 153 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 175
TABLE 154 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 175
TABLE 155 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 175
TABLE 156 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 176
11.3 EUROPE 176
TABLE 157 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION) 177
TABLE 158 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION) 177
TABLE 159 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 178
TABLE 160 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 178
TABLE 161 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 178
TABLE 162 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 179
11.3.1 GERMANY 179
11.3.1.1 Significant investments in R&D to support market growth 179
TABLE 163 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 180
TABLE 164 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 180
TABLE 165 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 180
TABLE 166 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 181
11.3.2 UK 181
11.3.2.1 Launch of new products and collaborations to support market growth in the UK in the coming years 181
TABLE 167 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION) 182
TABLE 168 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 182
TABLE 169 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 182
TABLE 170 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION) 183
11.3.3 FRANCE 183
11.3.3.1 Favorable government initiatives for immunization to support market growth in France 183
TABLE 171 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 184
TABLE 172 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 184
TABLE 173 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 184
TABLE 174 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 185
11.3.4 ITALY 185
11.3.4.1 Italy is the third-largest donor for the International Finance Facility for Immunization 185
TABLE 175 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 185
TABLE 176 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 186
TABLE 177 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 186
TABLE 178 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION) 186
11.3.5 SPAIN 187
11.3.5.1 Increasing investments in vaccine development by private organizations to support market growth in Spain 187
TABLE 179 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 187
TABLE 180 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 187
TABLE 181 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 188
TABLE 182 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION) 188
11.3.6 REST OF EUROPE 188
TABLE 183 ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 189
TABLE 184 ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION) 189
TABLE 185 ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 190
TABLE 186 ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION) 190
11.4 ASIA PACIFIC 191
TABLE 187 ASIA PACIFIC: HEALTHCARE EXPENDITURE PER CAPITA, BY COUNTRY,
2017 VS. 2018 VS. 2019 (USD) 191
FIGURE 29 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 192
TABLE 188 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION) 193
TABLE 189 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION) 193
TABLE 190 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 194
TABLE 191 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION) 194
TABLE 192 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 194
TABLE 193 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 195
11.4.1 CHINA 195
11.4.1.1 Growing investments in the biotechnology sector to drive market growth in China 195
TABLE 194 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 196
TABLE 195 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 196
TABLE 196 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 196
TABLE 197 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 197
11.4.2 JAPAN 197
11.4.2.1 Government initiatives for increasing the accessibility of vaccines to drive market growth in Japan 197
TABLE 198 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 197
TABLE 199 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 198
TABLE 200 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 198
TABLE 201 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 198
11.4.3 INDIA 199
11.4.3.1 Growth of the biotechnology sector and development of new vaccines to support market growth in India 199
TABLE 202 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 199
TABLE 203 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 200
TABLE 204 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 200
TABLE 205 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION) 200
11.4.4 SOUTH KOREA 201
11.4.4.1 Strong government boost to develop vaccine hubs in the country is expected to drive market growth 201
TABLE 206 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 201
TABLE 207 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION) 201
TABLE 208 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 202
TABLE 209 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 202
11.4.5 REST OF ASIA PACIFIC 202
TABLE 210 ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 203
TABLE 211 ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 203
TABLE 212 ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 203
TABLE 213 ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 204
11.5 LATIN AMERICA 204
TABLE 214 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION) 204
TABLE 215 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION) 205
TABLE 216 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 205
TABLE 217 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION) 206
TABLE 218 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 206
TABLE 219 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 206
11.5.1 BRAZIL 207
11.5.1.1 Rising focus on vaccination from governmental and non-governmental organizations to drive market growth 207
TABLE 220 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 207
TABLE 221 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 207
TABLE 222 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 208
TABLE 223 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION) 208
11.5.2 REST OF LATIN AMERICA 208
TABLE 224 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION) 209
TABLE 225 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 209
TABLE 226 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 209
TABLE 227 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION) 210
11.6 MIDDLE EAST AND AFRICA 210
11.6.1 HIGH DEMAND FOR VACCINES DUE TO THE PREVALENCE OF INFECTIOUS DISEASES WILL DRIVE MARKET GROWTH 210
TABLE 228 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION) 211
TABLE 229 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION) 211
TABLE 230 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION) 212
TABLE 231 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION) 212
TABLE 232 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION) 212
12 COMPETITIVE LANDSCAPE 213
12.1 OVERVIEW 213
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 214
FIGURE 30 KEY PLAYER STRATEGIES IN THE VACCINES MARKET, 2018-2021 214
12.3 MARKET SHARE ANALYSIS 215
FIGURE 31 VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020 215
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 216
FIGURE 32 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE VACCINES MARKET, 2016–2020 216
12.5 COMPANY EVALUATION QUADRANT 217
12.5.1 STARS 217
12.5.2 EMERGING LEADERS 217
12.5.3 PERVASIVE PLAYERS 217
12.5.4 PARTICIPANTS 217
FIGURE 33 VACCINES MARKET: COMPANY EVALUATION QUADRANT, 2020 218
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 219
12.6.1 PROGRESSIVE COMPANIES 219
12.6.2 STARTING BLOCKS 219
12.6.3 RESPONSIVE COMPANIES 219
12.6.4 DYNAMIC COMPANIES 219
FIGURE 34 VACCINES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020 220
12.7 DISEASE INDICATION FOOTPRINT OF COMPANIES 221
TABLE 233 DISEASE INDICATION PORTFOLIO ANALYSIS: VACCINES MARKET (2020) 221
12.8 REGIONAL FOOTPRINT OF COMPANIES 222
TABLE 234 REGIONAL FOOTPRINT ANALYSIS: VACCINES MARKET (2020) 222
12.9 COMPETITIVE SCENARIO 223
12.9.1 PRODUCT LAUNCHERS & APPROVALS 223
TABLE 235 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2018–NOVEMBER 2021 223
12.9.2 DEALS 225
TABLE 236 VACCINES MARKET: DEALS, JANUARY 2018–NOVEMBER 2021 225
12.9.3 OTHER DEVELOPMENTS 228
TABLE 237 VACCINES MARKET: OTHER DEVELOPMENTS,
JANUARY 2018–NOVEMBER 2021 228
13 COMPANY PROFILES 229
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1 KEY COMPANIES 229
13.1.1 GLAXOSMITHKLINE PLC 229
TABLE 238 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW 229
FIGURE 35 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2020) 230
13.1.2 MERCK & CO., INC. 237
TABLE 239 MERCK & CO., INC.: BUSINESS OVERVIEW 237
FIGURE 36 MERCK & CO., INC.: COMPANY SNAPSHOT (2020) 238
13.1.3 PFIZER, INC. 242
TABLE 240 PFIZER, INC.: BUSINESS OVERVIEW 242
FIGURE 37 PFIZER, INC.: COMPANY SNAPSHOT (2020) 243
13.1.4 SANOFI SA 248
TABLE 241 SANOFI SA: BUSINESS OVERVIEW 248
FIGURE 38 SANOFI SA: COMPANY SNAPSHOT (2020) 249
13.1.5 CSL LIMITED 254
TABLE 242 CSL LIMITED: BUSINESS OVERVIEW 254
FIGURE 39 CSL LIMITED: COMPANY SNAPSHOT (2020) 255
13.1.6 EMERGENT BIOSOLUTIONS, INC. 258
TABLE 243 EMERGENT BIOSOLUTIONS, INC.: BUSINESS OVERVIEW 258
FIGURE 40 MERGENT BIOSOLUTIONS, INC.: COMPANY SNAPSHOT (2020) 259
13.1.7 JOHNSON & JOHNSON 261
TABLE 244 JOHNSON & JOHNSON: BUSINESS OVERVIEW 261
FIGURE 41 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020) 262
13.1.8 ASTRAZENECA PLC 264
TABLE 245 ASTRAZENECA PLC: BUSINESS OVERVIEW 264
FIGURE 42 ASTRAZENECA PLC: COMPANY SNAPSHOT (2020) 265
13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD. 267
TABLE 246 SERUM INSTITUTE OF INDIA PVT. LTD.: BUSINESS OVERVIEW 267
13.1.10 BAVARIAN NORDIC A/S 271
TABLE 247 BAVARIAN NORDIC A/S: BUSINESS OVERVIEW 271
FIGURE 43 BAVARIAN NORDIC A/S: COMPANY SNAPSHOT (2020) 272
13.1.11 MITSUBISHI TANABE PHARMA CORPORATION 274
TABLE 248 MITSUBISHI TANABE PHARMA CORPORATION: BUSINESS OVERVIEW 274
13.1.12 DAIICHI SANKYO COMPANY, LIMITED 276
TABLE 249 DAIICHI SANKYO COMPANY, LIMITED: BUSINESS OVERVIEW 276
FIGURE 44 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2020) 276
13.1.13 PANACEA BIOTEC 278
TABLE 250 PANACEA BIOTEC: BUSINESS OVERVIEW 278
FIGURE 45 PANACEA BIOTEC: COMPANY SNAPSHOT (2020) 279
13.1.14 BIOLOGICAL E LIMITED 281
TABLE 251 BIOLOGICAL E LIMITED: BUSINESS OVERVIEW 281
13.1.15 BHARAT BIOTECH 284
TABLE 252 BHARAT BIOTECH: BUSINESS OVERVIEW 284
13.1.16 NOVAVAX, INC. 286
TABLE 253 NOVAVAX, INC.: BUSINESS OVERVIEW 286
FIGURE 46 NOVAVAX, INC.: COMPANY SNAPSHOT (2020) 286
13.1.17 FSUE NPO MICROGEN 288
TABLE 254 FSUE NPO MICROGEN: BUSINESS OVERVIEW 288
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER COMPANIES 289
13.2.1 SINOVAC BIOTECH LTD. 289
13.2.2 INCEPTA VACCINE LTD. 290
13.2.3 VALNEVA SE 290
13.2.4 VBI VACCINES INC. 291
13.2.5 PT BIO FARMA (PERSERO) 291
13.2.6 INOVIO PHARMACEUTICALS, INC. 292
13.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 292
13.2.8 INDIAN IMMUNOLOGICALS LIMITED 293
14 APPENDIX 294
14.1 DISCUSSION GUIDE 294
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 299
14.3 AVAILABLE CUSTOMIZATIONS 301
14.4 RELATED REPORTS 301
14.5 AUTHOR DETAILS 302
